Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...

Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular ...

Aldeyra Therapeutics (ALDX) announced that the U.S. Food and Drug Administration or FDA has accepted for review the resubmitted New Drug Application NDA for topical ocular reproxalap, a first-in-class ...

Developed by Aldeyra Therapeutics, reproxalap is a therapy to treat patients with the signs and symptoms of dry eye disease.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BellRing Brands (BRBR) been one of those stocks this year?

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...